These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17520827)

  • 21. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.
    Tao M; Park CH; Bihovsky R; Wells GJ; Husten J; Ator MA; Hudkins RL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):938-42. PubMed ID: 16290935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
    Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
    FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies Employed for the Development of PARP Inhibitors.
    Canan S; Maegley K; Curtin NJ
    Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors.
    Zhang WT; Ruan JL; Wu PF; Jiang FC; Zhang LN; Fang W; Chen XL; Wang Y; Cao BS; Chen GY; Zhu YJ; Gu J; Chen JG
    J Med Chem; 2009 Feb; 52(3):718-25. PubMed ID: 19125579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the effect of PARP-1 flexibility in docking studies.
    Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
    J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
    Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
    J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacophore model of integrin alphavbeta3 antagonists].
    Cheng GY; Ni GH; Jiang FC
    Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
    Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
    Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives.
    Pellicciari R; Camaioni E; Costantino G; Formentini L; Sabbatini P; Venturoni F; Eren G; Bellocchi D; Chiarugi A; Moroni F
    ChemMedChem; 2008 Jun; 3(6):914-23. PubMed ID: 18409175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3. Life or death decisions: the cast of poly(ADP-ribose)polymerase (PARP) as a therapeutic target for brain ischaemia.
    Pellicciari R; Camaioni E; Costantino G
    Prog Med Chem; 2004; 42():125-69. PubMed ID: 15003720
    [No Abstract]   [Full Text] [Related]  

  • 32. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.
    Loh VM; Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Eversley PJ; Gomez S; Hoare J; Kerrigan F; Matthews IT; Menear KA; Martin NM; Newton RF; Paul J; Smith GC; Vile J; Whittle AJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2235-8. PubMed ID: 15837300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of the pharmacophore model of acetylcholinesterase inhibitor.
    Zhu Y; Tong XY; Zhao Y; Chen H; Jiang FC
    Yao Xue Xue Bao; 2008 Mar; 43(3):267-76. PubMed ID: 18630262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor.
    Lord AM; Mahon MF; Lloyd MD; Threadgill MD
    J Med Chem; 2009 Feb; 52(3):868-77. PubMed ID: 19117416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
    Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
    Cao R
    J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.
    Wang LX; Zhou XB; Xiao ML; Jiang N; Liu F; Zhou WX; Wang XK; Zheng ZB; Li S
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3739-43. PubMed ID: 25086680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
    Sunderland PT; Woon EC; Dhami A; Bergin AB; Mahon MF; Wood PJ; Jones LA; Tully SR; Lloyd MD; Thompson AS; Javaid H; Martin NM; Threadgill MD
    J Med Chem; 2011 Apr; 54(7):2049-59. PubMed ID: 21417348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
    Zhu Q; Wang X; Chu Z; He G; Dong G; Xu Y
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1993-6. PubMed ID: 23481647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.